Sujal Shah
2015
In 2015, Sujal Shah earned a total compensation of $1.1M as Chief Financial Officer at Cymabay Therapeutics, a 53% increase compared to previous year.
Compensation breakdown
| Bonus | $59,325 |
|---|---|
| Option Awards | $688,860 |
| Salary | $339,000 |
| Other | $20,266 |
| Total | $1,107,451 |
Shah received $688.9K in option awards, accounting for 62% of the total pay in 2015.
Shah also received $59.3K in bonus, $339K in salary and $20.3K in other compensation.
Rankings
In 2015, Sujal Shah's compensation ranked 7,454th out of 13,638 executives tracked by ExecPay. In other words, Shah earned more than 45.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,454 out of 13,638 | 45th |
Division Manufacturing | 2,813 out of 5,190 | 46th |
Major group Chemicals And Allied Products | 1,017 out of 1,854 | 45th |
Industry group Drugs | 819 out of 1,528 | 46th |
Industry Pharmaceutical Preparations | 643 out of 1,182 | 46th |
Source: SEC filing on April 21, 2016.
Shah's colleagues
We found two more compensation records of executives who worked with Sujal Shah at Cymabay Therapeutics in 2015.
News
Cymabay Therapeutics CEO Sujal Shah's 2022 pay rises 16% to $2.6M
April 19, 2023
Cymabay Therapeutics CEO Sujal Shah's 2021 pay slips 16% to $2.2M
April 26, 2022
Cymabay Therapeutics CEO Sujal Shah's 2019 pay jumps 32% to $2.6M
May 15, 2020
Cymabay Therapeutics General Counsel Paul Quinlan receives $3M in 2018
April 26, 2019